Medicine for improving nerve growth factor level and preparation method thereof

Abstract

The invention discloses a medicine for improving nerve growth factor level and a preparation method thereof. The invention discloses a medicine for improving the level of nerve growth factors. The medicine comprises the following components in percentage by weight: 50-60% of grasshopper powder, 15-20% of cocoa powder and 25-30% of red date powder. The medicine is safe to take, and the content of nerve growth factor protein in the body can be effectively increased by taking the medicine.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, specifically to a drug that enhances the level of nerve growth factor and its preparation method. Background Technology

[0002] Multiple media outlets have reported that research suggests love is not determined by human will, but rather by the level of nerve growth factor protein in the human body. However, the level of nerve growth factor protein in the human body will naturally decline over time, causing love to fade and gradually evolve into friendship / family affection or deteriorate and break down.

[0003] Therefore, there is an urgent need to develop a safe and effective drug rich in nerve growth factor to increase the level of nerve growth factor protein in the body through oral administration. Summary of the Invention

[0004] The technical problem to be solved by this invention is to develop a drug and its preparation method for increasing the level of nerve growth factor in the human body.

[0005] To achieve the above objectives, one of the technical solutions adopted by the present invention is to provide a drug that enhances the level of nerve growth factor protein. The main ingredient of the drug includes grasshopper powder, and the excipients include cocoa powder and jujube powder. The grasshopper powder content is 50-60%, the cocoa powder content is 15-20%, and the jujube powder content is 25-30%.

[0006] In a second aspect to achieve the above-mentioned objective, the present invention also provides a method for preparing a drug that enhances the level of nerve growth factor, comprising the following steps: Step 1: Remove the wings and claws of the unmated male and female grasshoppers and freeze them to death.

[0007] Step 2: Clean the frozen grasshoppers with salt water and drain them.

[0008] Step 3: Place the drained grasshoppers in an oven and heat to 90℃ until they are baked and dried.

[0009] Step 4: Grind the dried grasshoppers into powder using a grinder.

[0010] Step 5: Grind the dried and pitted red dates into powder.

[0011] Step 6: Weigh out grasshopper powder, cocoa powder and jujube powder according to the drug ratio and mix them evenly.

[0012] Step 7: Then divide the mixed powder into bags (bottles) of fixed weight and seal them.

[0013] Step 8: Store the medicine in a cool, dry, well-ventilated, and dark environment at a temperature below 28°C.

[0014] Dosage: Oral administration. It can be taken with boiled water or mixed with honey to form a paste. Take one packet (bottle) once a day for three days.

[0015] Precautions for taking medication: People with allergies should use with caution.

[0016] Do not take with other medications at the same time.

[0017] The concept of love in this invention encompasses all romantic relationships and spousal relationships.

[0018] This embodiment is a powder, sweet in taste, and belongs to traditional Chinese medicine. The technical solution of this invention follows the objective law that the level of human nerve growth factor will naturally decline over time, leading to the natural fading of love and its gradual evolution into friendship / family affection or deterioration and breakup. It utilizes the achievements of traditional Chinese medicine combined with modern biology, neurophysiology, biochemistry and medical pharmacology research to use natural nerve growth factor from unmated male and female grasshoppers to increase the level of human nerve growth factor.

[0019] In this invention, the drug for enhancing nerve growth factor levels utilizes grasshoppers, an ideal, highly nutritious green food for humans, as well as a traditional Chinese medicine ingredient where the whole insect can be used medicinally, and which is non-toxic to humans. Cocoa powder can be used to make beverages, is a food ingredient, and is also a traditional Chinese medicine ingredient, and is non-toxic to humans. Red date powder is both a food and a traditional Chinese medicine ingredient, and is non-toxic to humans. Currently, grasshopper farming is professionally carried out in various regions, and the market for grasshoppers is vast.

[0020] In this embodiment, the grasshoppers are artificially bred species suitable for human consumption and medicinal use, such as the Oriental migratory locust, the Chinese rice locust, the cotton locust, and the Chinese grasshopper, both male and female. The medicine in this embodiment is an artificially bred Oriental migratory locust.

[0021] In this invention, the mating male and female grasshoppers refer to male and female grasshoppers that are currently mating, while the non-mating male and female grasshoppers refer to male and female grasshoppers that are not currently mating.

[0022] The cocoa powder used in this invention is natural cocoa powder and alkalized cocoa powder that have passed the internationally recognized ISO22000 food safety management system certification. In this embodiment, the drug uses alkalized cocoa powder.

[0023] The red dates mentioned in this invention are dried and pitted red dates. In this embodiment, the medicine uses dried and pitted red dates sold in the market.

[0024] The grasshopper powder in this invention is rich in natural nerve growth factor, which can increase the level of nerve growth factor in the human body and reverse hormonal changes in emotions. Cocoa powder can help improve relationships between couples by regulating emotions, and jujube powder has an anti-allergic effect for those with allergies or drug allergies.

[0025] Nerve growth factor (NGF) is a protein composed of amino acids. It is a naturally occurring bioactive protein in the animal nervous system and is found in humans and many other animals. In medicine, nerve growth factor is referred to as a drug and belongs to the category of protein drugs.

[0026] Nerve growth factor (NGF) can promote the growth, development, differentiation and maturation of central and peripheral neurons, maintain the normal function of the nervous system and accelerate the repair of nervous system damage.

[0027] Nerve growth factor (NGF) can treat nervous system diseases. It uses natural animal nerve growth factors to promote nerve growth and repair damaged nerves, thereby curing nervous system diseases.

[0028] Nerve growth factor (NGF) can guide love. This method of using NGF to guide love involves using natural animal nerve growth factor to increase the level of nerve growth factor in the human body. Since nerve growth factor is medically termed a drug, this invention is referred to as a drug for increasing nerve growth factor levels. Attached Figure Description

[0029] Figure 1 This is a standard curve diagram from the grasshopper nerve growth factor detection experiment of this invention.

[0030] Figure 2 This is a standard curve diagram from the grasshopper androgen detection experiment of this invention.

[0031] Figure 3 This is a standard curve diagram from the grasshopper estrogen detection experiment of this invention.

[0032] Figure 4 This is a standard curve diagram from the pre-clinical trial of the present invention.

[0033] Figure 5 This is a standard curve diagram of the clinical trials following the introduction of the drug.

[0034] The drug experiments of this invention are as follows: I. Animal Experiment: Detection of Nerve Growth Factor (NGF) in Grasshoppers Detection method: Enzyme-linked immunosorbent assay (ELISA), with a limit of detection of less than 1.0 pg / mL.

[0035] 1. Sample collection method: Tissue homogenization: Add an appropriate amount of physiological saline to the tissue and homogenize it. Centrifuge at 3000 rpm for 10 minutes and collect the supernatant.

[0036] 2. Operating steps: Remove the required strips from the aluminum foil bag after equilibration at room temperature for 20 minutes, and seal the remaining strips in a resealable bag and return them to 4°C.

[0037] Set up standard wells and sample wells, and add 50 μL of standard at different concentrations to each standard well; Add 10 μL of the sample to be tested to the sample well first, then add 40 μL of sample diluent; do not add any to the blank well.

[0038] Except for the blank wells, add 100 μL of horseradish peroxidase (HRP)-labeled detection antibody to each of the standard and sample wells, seal the reaction wells with sealing film, and incubate at 37°C in a water bath or incubator for 60 minutes.

[0039] Discard the liquid, pat dry on absorbent paper, fill each well with washing liquid, let stand for 1 minute, shake off the washing liquid, pat dry on absorbent paper, and repeat this washing process 5 times (or you can use a plate washer).

[0040] Add 50 μL each of substrate A and B to each well and incubate at 37°C in the dark for 15 minutes.

[0041] Add 50 μL of stop solution to each well, and measure the OD value of each well at a wavelength of 450 nm within 15 minutes.

[0042] 3. Result Interpretation: Plotting the standard curve: In Table 1, plot the linear regression curve of the standard with the concentration of the standard on the vertical axis and the corresponding OD value on the horizontal axis, and calculate the concentration value of each sample according to the curve equation.

[0043] 4. Attached diagram of the standard curve for this experiment Figure 1 As shown.

[0044] Table 1

[0045] 5. The sample sequences are shown in Table 2.

[0046] Table 2

[0047] As shown in the table above, the samples are sorted into mated and unmated males and females according to their Chinese descriptions.

[0048] 6. Sample OD values ​​are shown in Table 3.

[0049] Table 3

[0050] As can be seen from the table above, the data are the original NGF data of the corresponding sample sequences.

[0051] 7. Sample data processing is shown in Table 4.

[0052] Table 4

[0053] As can be seen from the table above, the data are the original data of the corresponding sample sequences after preliminary processing.

[0054] 8. The NGF concentrations of the samples are shown in Table 5 (unit: pg / mL).

[0055] Table 5

[0056] As shown in the table above, the data represents the NGF concentration of the corresponding sample sequences.

[0057] 9. The mean NGF concentration of the samples is shown in Table 6 (unit: pg / mL).

[0058] Table 6

[0059] 10. Conclusion: The experimental results show that the NGF content of unmated male grasshoppers is significantly higher than that of mated male grasshoppers; the NGF content of unmated female grasshoppers is significantly higher than that of mated female grasshoppers.

[0060] The drug of this invention increases the level of nerve growth factor (NGF) protein in human blood. Since the raw material, grasshoppers, is relatively small, this invention allows for the use of the whole grasshopper. Experimental results show that unmated male and female grasshoppers are rich in NGF, suggesting that the drug of this invention has a very high NGF content, supporting its effectiveness.

[0061] II. Animal Experiment: Androgen Detection in Grasshoppers Detection method: Enzyme-linked immunosorbent assay (ELISA), with a limit of detection of less than 0.1 ng / mL.

[0062] 1. Sample collection method: Tissue homogenization: Add an appropriate amount of physiological saline to the tissue and homogenize. Centrifuge at 3000 rpm for 10 minutes and collect the supernatant.

[0063] 2. Operating steps: Remove the required strips from the aluminum foil bag after equilibration at room temperature for 20 minutes, and seal the remaining strips in a resealable bag and return them to 4°C.

[0064] Set up standard wells and sample wells, and add 50 μL of standard at different concentrations to each standard well; Add 10 μL of the sample to be tested to the sample well first, then add 40 μL of sample diluent; do not add to the empty well.

[0065] Except for the blank wells, add 100 μL of horseradish peroxidase (HRP)-labeled detection antibody to each of the standard and sample wells, seal the reaction wells with sealing film, and incubate at 37°C in a water bath or incubator for 60 minutes.

[0066] Discard the liquid, pat dry on absorbent paper, fill each well with washing solution, let stand for 1 minute, shake off the washing solution, pat dry on absorbent paper, and repeat this washing process 5 times (or you can use a plate washer).

[0067] Add 50 μL each of substrate A and B to each well and incubate at 37°C in the dark for 15 minutes.

[0068] Add 50 μL of stop solution to each well, and measure the OD value of each well at a wavelength of 450 nm within 15 minutes.

[0069] 3. Result Interpretation: Plotting the Standard Curve: In Table 7, plot the linear regression curve of the standard with the concentration of the standard on the vertical axis and the corresponding OD value on the horizontal axis. Calculate the concentration value of each sample according to the curve equation.

[0070] Table 7

[0071] 4. The standard curve for this experiment is as follows: Figure 2 As shown.

[0072] 5. Sample sequence list 8.

[0073] Table 8

[0074] As can be seen from the table above, the samples are sorted according to whether they are mated or not.

[0075] 6. Sample OD values ​​are shown in Table 9 (original sample data). Table 9

[0076] As shown in the table above, the data are the raw androgen data of the corresponding sample sequences.

[0077] 7. Sample concentrations are shown in Table 10. (Unit: ng / mL) Table 10

[0078] As shown in the table above, the data represents the androgen concentration of the corresponding sample sequences.

[0079] 8. The mean concentration of the samples is shown in Table 11 (unit: ng / mL).

[0080] Table 11

[0081] 9. Conclusion: The experimental results show that the male grasshoppers secreted abundant androgens during mating, while no androgens were detected in the unmated male grasshoppers. The fact that no androgens were detected in the unmated male grasshoppers suggests that the drug of this invention does not contain androgens.

[0082] III. Animal experiments: Detection of estrogen in grasshoppers, detection method: enzyme-linked immunosorbent assay (ELISA); limit of detection less than 1.0 pg / mL.

[0083] 1. Sample collection method: Tissue homogenization: Add an appropriate amount of physiological saline to the tissue and homogenize. Centrifuge at 3000 rpm for 10 minutes and collect the supernatant.

[0084] 2. Operating steps: Remove the required strips from the aluminum foil bag after equilibration at room temperature for 20 minutes, and seal the remaining strips in a resealable bag and return them to 4°C.

[0085] Set up standard wells and sample wells, and add 50 μL of standard at different concentrations to each standard well; Add 10 μL of the sample to be tested to the sample well first, then add 40 μL of sample diluent; do not add any to the blank wells. Except for the blank wells, add 100 μL of horseradish peroxidase (HRP)-labeled detection antibody to each of the standard and sample wells, seal the reaction wells with sealing film, and incubate at 37°C in a water bath or incubator for 60 minutes.

[0086] Discard the liquid, pat dry on absorbent paper, fill each well with washing solution, let stand for 1 minute, shake off the washing solution, pat dry on absorbent paper, and repeat this washing process 5 times (or you can use a plate washer).

[0087] Add 50 μL each of substrate A and B to each well and incubate at 37°C in the dark for 15 minutes.

[0088] Add 50 μL of stop solution to each well, and measure the OD value of each well at a wavelength of 450 nm within 15 minutes.

[0089] 3. Result Interpretation: Plotting the standard curve: In Table 12, plot the linear regression curve of the standard with the concentration of the standard on the vertical axis and the corresponding OD value on the horizontal axis, and calculate the concentration value of each sample according to the curve equation.

[0090] 4. The standard curve for this experiment is attached. Figure 3 As shown.

[0091] Table 12

[0092] 5. Sample sequence list 13.

[0093] Table 13

[0094] As shown in the table above, the samples are sorted according to the non-mating categories in the mating process. 6. Sample OD values, Table 14 (original sample data).

[0095] Table 14

[0096] As can be seen from the table above, the data are the raw estrogen data of the corresponding sample sequences.

[0097] 7. Sample Concentration Table 15 (Unit: pg / mL) Table 15

[0098] As shown in the table above, the data represents the estrogen concentration of the corresponding sample sequences.

[0099] 8. The mean concentration of the samples is shown in Table 16 (unit: pg / mL). Table 16

[0100] 9. Conclusion: The experimental results show that the female grasshoppers in the mating group secreted very abundant estrogen, while no estrogen was detected in the unmated female grasshoppers. The fact that no estrogen was detected in the unmated female grasshoppers suggests that the drug of this invention does not contain detectable estrogen.

[0101] IV. Pre-drug clinical trial: This experiment is an exploratory study. Detection method: enzyme-linked immunosorbent assay (ELISA), limit of detection 6.1 pg / mL.

[0102] 1. Sample collection Whole blood samples collected in serum separation tubes are left at room temperature for 2 hours or overnight at 4°C, and then centrifuged at 1000×g for 20 minutes to collect the supernatant.

[0103] 2. Operating Procedures Sample addition: Set up separate wells for standards, test samples, and blanks. Set up 7 standard wells and add 100 μL of different concentrations of standards to each well sequentially. Add 100 μL to the blank wells and 100 μL to the remaining test samples. Cover the ELISA plate with a membrane and incubate at 37°C for 2 hours.

[0104] Discard the liquid, shake dry, no washing required.

[0105] Add 100 μL of detection solution A working solution to each well, cover the microplate with a membrane, and incubate at 37°C for 1 hour.

[0106] Discard the liquid in the wells, wash each well with 300 μL of washing solution, soak for 1-2 minutes, aspirate or shake off the liquid in the microplate, place several layers of absorbent paper on the lab bench, tap the microplate firmly several times, repeat the washing process 3 times, and after the last wash, shake off the washing solution completely from the wells.

[0107] Add 100 μL of working solution B to each well, cover with a membrane, and incubate at 37°C for 1 hour.

[0108] Discard the liquid in the well, shake dry, and wash the plate 5 times, following the same method as step four.

[0109] Add 90 μL of substrate solution to each well, cover the microplate with a membrane, and incubate at 37°C in the dark. The incubation period can be stopped when there is a clear gradient of blue in the first 3-4 wells and no clear gradient in the last 3-4 wells.

[0110] Add 50 μL of stop solution to each well to stop the reaction; the blue color will immediately turn yellow. The stop solution should be added in the same order as the substrate solution. If uneven coloring occurs, gently shake the plate to mix the solutions thoroughly.

[0111] After ensuring that there are no water droplets on the bottom of the ELISA plate and no air bubbles in the wells, immediately measure the optical density (0.D. value) of each well at a wavelength of 450 nm using an ELISA reader.

[0112] 3. Draw the standard curve based on Table 17. (This refers to the standard curve used in this experiment.) Figure 4 As shown.

[0113] Table 17

[0114] 4. Result Calculation: Based on the absorbance of the standard curve, with the y-axis representing concentration and the x-axis representing OD values, the standard curve plotting software (Curve Expert 1.4) automatically generates the calculation equation. Based on the equation... Given a=2.31423038758E-001, b=6.29147890280E+001, c=-3.80393029597E+002, d=2.22003645735E+003, substitute these values ​​into the OD values ​​of the samples to calculate the corresponding concentrations.

[0115] 5. Sample OD values, Table 18.

[0116] Table 18

[0117] As can be seen from the table above, the sample OD value (absorbance) is the raw NGF data of the clinical trial participants before they took the drug.

[0118] 6. Sample concentrations of NGF (unit: pg / mL) are shown in Table 19.

[0119] Table 19

[0120] As can be seen from the table above, the sample Y value represents the NGF concentration of the participants before they took the medication.

[0121] V. Post-drug clinical trials This experiment is an exploratory study. The detection method is enzyme-linked immunosorbent assay (ELISA), with a limit of detection of 6.1 pg / mL.

[0122] 1. Sample collection Whole blood samples collected in serum separation tubes are left at room temperature for 2 hours or overnight at 4°C, and then centrifuged at 1000×g for 20 minutes to collect the supernatant.

[0123] 2. Operating Procedures Sample addition: Set up separate wells for standards, test samples, and blanks. Set up 7 standard wells and add 100 μL of different concentrations of standards to each well sequentially. Add 100 μL to the blank wells and 100 μL to the remaining test samples. Cover the ELISA plate with a membrane and incubate at 37°C for 2 hours.

[0124] Discard the liquid, shake dry, no washing required.

[0125] Add 100 μL of detection solution A working solution to each well, cover the microplate with a membrane, and incubate at 37°C for 1 hour.

[0126] Discard the liquid in the wells, wash each well with 300 μL of washing solution, soak for 1-2 minutes, aspirate or shake off the liquid in the microplate, place several layers of absorbent paper on the lab bench, tap the microplate face down several times, repeat the washing process 3 times, and after the last wash, shake off the washing solution completely from the wells.

[0127] Add 100 μL of working solution B to each well, cover with a membrane, and incubate at 37°C for 1 hour.

[0128] Discard the liquid in the well, shake dry, and wash the plate 5 times, following the same method as step four.

[0129] Add 90 μL of substrate solution to each well, cover the microplate with a membrane, and incubate at 37°C in the dark. The incubation period can be stopped when there is a clear gradient of blue in the first 3-4 wells and no clear gradient in the last 3-4 wells.

[0130] Add 50 μL of stop solution to each well to stop the reaction; the blue color will immediately turn yellow. The stop solution should be added in the same order as the substrate solution. If uneven coloring occurs, gently shake the plate to mix the solutions thoroughly.

[0131] After ensuring that there are no water droplets on the bottom of the ELISA plate and no air bubbles in the wells, immediately measure the optical density (0.D. value) of each well at a wavelength of 450 nm using an ELISA reader.

[0132] 3. Draw the standard curve based on Table 20. The standard curve for this experiment is as follows: Figure 5 As shown.

[0133] Table 20

[0134] 4. Result Calculation: Based on the absorbance of the standard curve, with the y-axis representing concentration and the x-axis representing OD values, the standard curve plotting software (Curve Expert 1.4) automatically generates the calculation equation. Based on the equation... Substitute the OD values ​​of the samples to calculate the corresponding concentrations: a = 1.51690768688E+000, b = 2.91685719617E+001, c = -2.35987785669E+000, d = 1.49435855963E+000.

[0135] 5. Sample OD values ​​are shown in Table 21.

[0136] Table 21

[0137] As can be seen from the table above: the sample OD value (absorbance) is the raw NGF data after the clinical trial participants took the drug. 6. Sample concentrations of NGF (unit: pg / mL) are shown in Table 22. Table 22

[0138] As can be seen from the table above, the sample Y value represents the NGF concentration after the participants took the medication.

[0139] 7. Comparison of NGF (unit pg / mL) data before and after drug administration in clinical trials (Table 23).

[0140] Table 23

[0141] Conclusion: Through 6 clinical trials, the NGF content was significantly increased after medication compared with that before medication.

[0142] Exploratory human clinical trials are only for preliminary verification of the feasibility of the technical solution and the efficacy of the drug.

[0143] Suitable for all couples and spouses, both men and women.

[0144] The examples illustrate the efficacy of the drug of the present invention in 6 clinical cases, as detailed below: Clinical Cases 1 and 2 Ms. Huang, 26 years old, and Mr. Li, 30 years old. Before taking the medication, Ms. Huang's initial blood NGF level was 4.9981 pg / mL, and Mr. Li's initial blood NGF level was 4.0119 pg / mL. After the blood tests, the couple took the medication once every 3 days. Two months later, Ms. Huang's NGF level was again measured at 8.6561 pg / mL, and Mr. Li's was again measured at 7.9813 pg / mL. Neither experienced any adverse reactions after taking the medication, and their NGF levels were significantly higher after starting the medication compared to before.

[0145] Clinical Cases 3 and 4 Mr. Zhu, 40 years old, and his wife, Ms. He, 36 years old. Before taking the medication, Mr. Zhu's initial blood NGF level was 3.9538 pg / mL, and Ms. He's initial blood NGF level was 3.4950 pg / mL. After the blood tests, the couple took the medication once every three days. Two months later, Mr. Zhu's NGF level was again measured at 7.4256 pg / mL, and Ms. He's was again measured at 6.8477 pg / mL. Neither experienced any adverse reactions after taking the medication, and the NGF levels were significantly higher after starting the medication compared to before.

[0146] Clinical Cases 5 and 6 Mr. Liu, 36 years old. His wife, Ms. Yang, 34 years old. Before taking the medication, Mr. Liu's initial blood NGF level was 4.1483 pg / mL, and Ms. Yang's initial blood NGF level was 3.7599 pg / mL. After the blood tests, the couple took the medication once every 3 days as instructed. Two months later, Mr. Liu's NGF level was again 8.4758 pg / mL, and Ms. Yang's NGF level was again 7.3710 pg / mL. Neither of them experienced any adverse reactions after taking the medication, and their NGF levels were significantly higher after taking the medication compared to before.

[0147] The above are merely preferred embodiments of the present invention and do not limit the scope of the patent. Any equivalent structural or procedural transformations made based on the description and drawings of the present invention, or direct or indirect applications in other related technical fields, are similarly included within the scope of patent protection of the present invention.

[0148] The key to the technical solution of this invention is to use unmated male and female grasshoppers, both of which have very high levels of nerve growth factor and whose hormones are undetectable, to formulate a drug that can increase the level of nerve growth factor in the human body.

[0149] The drug of this invention does not contain any male or female hormones, and will not cause excessive secretion of sex hormones in the body when taken by humans, thus disrupting the body's hormonal balance and harming human health. Detailed Implementation

[0150] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of the embodiments will be clearly and completely described below. Obviously, the described embodiments are only some, not all, of the embodiments of this disclosure. All other embodiments obtained by those skilled in the art based on the described embodiments of this disclosure without creative effort are within the scope of protection of this disclosure.

[0151] Unless otherwise stated, the raw materials used in the following examples are all commercially available products or can be prepared by known methods.

[0152] Example 1 A drug that enhances nerve growth factor levels is formulated with 50% grasshopper powder, 20% cocoa powder, and 30% jujube powder, with each serving of the finished drug weighing 4g.

[0153] The grasshopper powder mentioned above is made from unmated male and female grasshoppers. The grasshoppers are artificially bred Oriental migratory locusts suitable for human consumption and medicinal use. The cocoa powder is alkalized cocoa powder, and the red dates are dried, pitted red dates sold in the market.

[0154] The above drug preparation method: Unmated male and female grasshoppers had their wings and claws removed and were frozen to death.

[0155] Wash the frozen grasshoppers with salt water and drain them.

[0156] Place the drained grasshoppers in an oven and heat to 90℃ until they are baked and dried.

[0157] The dried grasshoppers were ground into powder using a grinder.

[0158] Next, grind the dried and pitted red dates into powder.

[0159] Weigh out grasshopper powder, cocoa powder, and jujube powder according to the drug formula, and mix them evenly.

[0160] Then repackage the mixed powder into 4g bags (or bottles) and seal them.

[0161] Then store the medicine in a cool, dry, well-ventilated, and dark environment at a temperature below 28°C.

[0162] Dosage: Oral administration. It can be taken with boiled water or mixed with honey to form a paste. Take one packet (bottle) once a day for three days.

[0163] Example 2: A drug that enhances nerve growth factor levels is formulated with 55% grasshopper powder, 17.5% cocoa powder, and 27.5% jujube powder, with each serving of the finished drug weighing 4g.

[0164] The grasshopper powder mentioned above is made from unmated male and female grasshoppers. The grasshoppers are artificially bred Oriental migratory locusts suitable for human consumption and medicinal use. The cocoa powder is alkalized cocoa powder, and the red dates are dried, pitted red dates sold in the market.

[0165] The above drug preparation method: Unmated male and female grasshoppers had their wings and claws removed and were frozen to death.

[0166] Wash the frozen grasshoppers with salt water and drain them.

[0167] Place the drained grasshoppers in an oven and heat to 90℃ until they are baked and dried.

[0168] The dried grasshoppers were ground into powder using a grinder.

[0169] Next, grind the dried and pitted red dates into powder.

[0170] Weigh out grasshopper powder, cocoa powder, and jujube powder according to the drug formula, and mix them evenly.

[0171] The mixed powder is then divided into 4g weight bags (bottles) and sealed.

[0172] Then store the medicine in a cool, dry, well-ventilated, and dark environment at a temperature below 28°C.

[0173] Dosage: Oral administration. It can be taken with boiled water or mixed with honey to form a paste. Take one packet (bottle) once a day for three days.

[0174] Example 3: A drug that enhances nerve growth factor levels is formulated with 60% grasshopper powder, 15% cocoa powder, and 25% jujube powder, with each serving of the finished drug weighing 4g.

[0175] The grasshopper powder mentioned above is made from unmated male and female grasshoppers. The grasshoppers are artificially bred Oriental migratory locusts suitable for human consumption and medicinal use. The cocoa powder is alkalized cocoa powder, and the red dates are dried, pitted red dates sold in the market.

[0176] The above drug preparation method: Unmated male and female grasshoppers had their wings and claws removed and were frozen to death.

[0177] Wash the frozen grasshoppers with salt water and drain them.

[0178] Place the drained grasshoppers in an oven and heat to 90℃ until they are baked and dried.

[0179] The dried grasshoppers were ground into powder using a grinder.

[0180] Next, grind the dried and pitted red dates into powder.

[0181] Weigh out grasshopper powder, cocoa powder, and jujube powder according to the drug formula, and mix them evenly.

[0182] The mixed powder is then repackaged into 4g bags or sealed bottles.

[0183] Then store the medicine in a cool, dry, well-ventilated, and dark environment at a temperature below 28°C.

[0184] Dosage: Oral administration. It can be taken with boiled water or mixed with honey to form a paste. Take one packet (bottle) once a day for three days.

Claims

1. A drug for increasing nerve growth factor levels, characterized in that, The medicine includes grasshopper powder, cocoa powder, and jujube powder, with grasshopper powder accounting for 50-60%, cocoa powder accounting for 15-20%, and jujube powder accounting for 25-30%.

2. The drug for increasing nerve growth factor levels according to claim 1, characterized in that, The grasshopper powder is made from unmated male and female grasshoppers.

3. The drug for increasing nerve growth factor levels according to claim 1, characterized in that, The grasshoppers mentioned are artificially bred species suitable for human consumption and medicinal use, such as the Oriental migratory locust, the Chinese rice locust, the cotton locust, and the Chinese grasshopper, including both male and female grasshoppers.

4. The drug for increasing nerve growth factor levels according to claim 1, characterized in that, The cocoa powder is made from natural cocoa powder or alkalized cocoa powder.

5. The drug for increasing nerve growth factor levels according to claim 1, characterized in that, The jujubes mentioned are dried and pitted jujubes.

6. The drug for increasing nerve growth factor levels according to claim 1, characterized in that, The preparation method includes the following steps: Unmated male and female grasshoppers were winged and clawed off and frozen to death. Wash the frozen grasshoppers with salt water and drain them. Place the drained grasshoppers in an oven and heat to 90℃ until they are baked and dried. The dried grasshoppers were ground into powder using a grinder. Next, grind the dried, pitted red dates into powder; Weigh out grasshopper powder, cocoa powder, and jujube powder according to the drug formula, and mix them evenly. The mixed powder is then repackaged into bags or bottles of a set weight and sealed. Then store the medicine in a cool, dry, well-ventilated, and dark environment at a temperature below 28°C.

Images